- Philstar.com
- The Philippine Star
- Pilipino Star Ngayon
- The Freeman
- Pang-Masa
- Banat
- Interaksyon
- Coupons
SUPPORT PHILSTAR
About Us |
Contact Us |
Advertise |
Privacy Policy |
Member Agreement |
Copyright Notice
Copyright © 2024. Philstar Global Corp. All Rights Reserved
X
+ Follow FENOFIBRATE INTERVENTION AND EVENT LOWERING Tag
Array ( [results] => Array ( [0] => Array ( [ArticleID] => 411036 [Title] => Delaying diabetic retinopathy [Summary] => The results of the FIELD (Fenofibrate Intervention and Event Lowering in Diabetes) study confirmed fenofibrate’s ... [DatePublished] => 2008-10-30 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [1] => Array ( [ArticleID] => 57893 [Title] => Treating diabetic retinopathy [Summary] => [DatePublished] => 2008-04-24 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [2] => Array ( [ArticleID] => 289788 [Title] => Managing metabolic syndrome with fenofibrates [Summary] => Fenofibrate has been shown to reduce risk of coronary events, including non-fatal heart attack and stroke, in patients with metabolic syndrome.
A study demonstrated the benefits of fenofibrate therapy in atherogenic dyslipidemia, a common risk factor for metabolic syndrome, a constellation of risk factors which also include obesity, insulin resistance and hypertension.
Atherogenic dyslipidemia is characterized by high-triglycerides, low high-density lipoprotein (HDL) and the preponderance of small low-density lipoprotein.
[DatePublished] => 2005-08-04 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) ) )
FENOFIBRATE INTERVENTION AND EVENT LOWERING
Array ( [results] => Array ( [0] => Array ( [ArticleID] => 411036 [Title] => Delaying diabetic retinopathy [Summary] => The results of the FIELD (Fenofibrate Intervention and Event Lowering in Diabetes) study confirmed fenofibrate’s ... [DatePublished] => 2008-10-30 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [1] => Array ( [ArticleID] => 57893 [Title] => Treating diabetic retinopathy [Summary] => [DatePublished] => 2008-04-24 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [2] => Array ( [ArticleID] => 289788 [Title] => Managing metabolic syndrome with fenofibrates [Summary] => Fenofibrate has been shown to reduce risk of coronary events, including non-fatal heart attack and stroke, in patients with metabolic syndrome.
A study demonstrated the benefits of fenofibrate therapy in atherogenic dyslipidemia, a common risk factor for metabolic syndrome, a constellation of risk factors which also include obesity, insulin resistance and hypertension.
Atherogenic dyslipidemia is characterized by high-triglycerides, low high-density lipoprotein (HDL) and the preponderance of small low-density lipoprotein.
[DatePublished] => 2005-08-04 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) ) )
abtest
October 30, 2008 - 12:00am
August 4, 2005 - 12:00am
Recommended
Lotto Sep 19, 2024
EZ2 - 12 21
SUERTRES - 2 1 3
6D Lotto - 7 5 9 3 0 1
6/42 Lotto - 5 26 2 21 8 27
P19,033,913.00
6/49 Super Lotto - 32n 24 38 35 15
P62,95,035.00
Forex
February 12, 2018
- 12:00 am
- 12:00 am
1$ : P51.66